Floatz logo

Alirocumab

Hyperlipidemias

Population Health Research Institutemonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Hyperlipidemias cohort.

Asset / SponsorPhaseRating
Lipitor
Poznan University of Medical Sciences
Phase 4BBB
Rosuvastatin
Nanjing First Hospital, Nanjing Medical University
Phase 4BBB
PRAVASTATIN
University of North Carolina, Chapel Hill
Phase 4BBB
Ezetimibe
NewAmsterdam Pharma
Phase 4BBB
Fenofibrate
Ospedale di Circolo - Fondazione Macchi
Phase 4BB

View all 36 →

Same molecule, other indications

Alirocumab is also rated in:

HypercholesterolemiaDormant
BB
Indicative ·
68 / 100
View asset →
inherited lipid metabolism disorderDormant
BB
Indicative ·
66 / 100
View asset →
acute coronary syndromeDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →